India's Piramal Pharma rises after JM Financial initiates with Street-high target price
** Shares of Piramal Pharma PIRM.NS rise 5.1% to 264.05
rupees
** JM Financial Institutional Securities starts coverage
with a "buy" and TP of 340 rupees, a Street-high, per data
compiled by LSEG
** TP at 35% premium to stock's previous close
** PIRM's differentiated offerings, global manufacturing
presence and end-to-end capabilities will help to capitalise on
the ongoing contract drug manufacturing industry expansion -
note
** Brokerage sees margin expansion on increasing
contribution from on-patent manufacturing
** PIRM stock up ~91% YTD vs 24% gains in 2023
(Reporting by Vijay Malkar)
((VijayDattaram.Malkar@thomsonreuters.com;))
Recent news on Piramal Pharma (Mumbai)
See all newsBrief: Piramal Pharma (Mumbai) Says Commercial Arrangement With Bayer Pharmaceuticals To Expire On December 31, 2026
Brief: Piramal Pharma (Mumbai) Says Tax Authority Confirms Demand Of 40.6 Million Rupees And Imposes Equivalent Penalty
India's Piramal Pharma falls after US FDA observations at UK facility
Brief: Piramal Pharma Says US FDA Issues Form-483 With 7 Observations To Morpeth UK Facility
Brief: Piramal Pharma Approves Exercise Of Call Option For Acquisition Of Additional 41% Equity In Yapan Bio